Physician profile
Nehal K Bhatt
NPI 1255406377
$370,973.33
in general payments reported to CMS, 2019-2025
27 companies · $3,766 in 2025
The $3,766 reported for 2025 was more than what 86% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $20K · 2021: $74K · 2022: $63K · 2023: $114K · 2024: $85K · 2025: $3,766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $173K · Travel and Lodging: $26K · Food and Beverage: $3,544 · Education: $83.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $172,838.50 |
| Travel and Lodging | $26,296.13 |
| Food and Beverage | $3,544.04 |
| Education | $83.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $318,001.61 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Mylan Specialty L.P. | $18,644.44 | 2019-2024 | Yupelri |
| United Therapeutics Corporation | $17,015.39 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11,901.88 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Viatris Specialty LLC | $3,408.30 | 2025 | Yupelri |
| Insmed, INC. | $462.57 | 2019-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $286.19 | 2019-2023 | Uptravi, Opsumit |
| Grifols USA, LLC | $208.87 | 2019-2023 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals LP | $206.16 | 2019-2025 | Tezspire |
| Intuitive Surgical, INC. | $168.13 | 2022 | |
| Harmony Biosciences LLC | $122.81 | 2020-2023 | Wakix |
| Merck Sharp & Dohme LLC | $104.71 | 2024-2025 | Winrevair |
| Takeda Pharmaceuticals U.S.A., INC. | $61.21 | 2022-2024 | Glassia |
| Sunovion Pharmaceuticals INC. | $50.89 | 2019 | |
| Abbvie INC. | $45.93 | 2023-2024 | Avycaz, Teflaro |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noctrix Health, INC. | $38.44 | 2024 | Nidra |
| Advanced Respiratory, INC | $28.90 | 2019-2021 | |
| Genzyme Corporation | $27.23 | 2025 | |
| Genentech USA, INC. | $27.00 | 2019 | |
| Ethicon INC. | $24.63 | 2019 | |
| Jazz Pharmaceuticals INC. | $24.61 | 2021 | |
| Mallinckrodt Hospital Products INC. | $23.80 | 2021 | |
| Resmed Corp | $19.90 | 2024 | |
| Shionogi INC | $19.73 | 2023 | Fetroja |
| Novartis Pharmaceuticals Corporation | $18.48 | 2023 | |
| Astellas Pharma US INC | $15.85 | 2022 | |
| Amgen INC. | $15.67 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nehal Bhatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.